AstraZeneca and Bristol Myers Squibb Discuss Potential Merger

AstraZeneca and Bristol Myers Squibb have reportedly discussed a merger, marking significant interest in major pharmaceutical alliances. The conversation comes as rising interest rates affect market dynamics. This potential merger could reshape the pharmaceutical industry landscape. For investors, the implications of such a merger might lead to changes in stock performance and market strategies surrounding these companies' shares.